NCT04262466 2026-03-06
Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
Immunocore Ltd
Phase 1/2 Active not recruiting
Clinical Trials
4 trialsNCT07131345 2025-08-20
Study of Iparomlimab and Tuvonralimab Plus Chemotherapy in Malignant Mesothelioma
National Cancer Center, China
Phase 1/2 Not yet recruiting
NCT02649829 2025-04-29
MESODEC
University Hospital, Antwerp
Phase 1/2 Completed
NCT01211275 2017-02-28
N08CPA
The Netherlands Cancer Institute
Phase 1/2 Completed